MGC Pharmaceuticals is developing cannabis-based pharmaceutical products, initially in Australia and Europe. It has cannabis-growing operations in Europe and plans to supply cannabis-based active pharmaceutical ingredients (API), as well as developing registered pharmaceutical products for refractory epilepsy and dementia. MGC has signed a binding term sheet for the sale of its MGC Derma cannabis-based cosmetics business to Cannaglobal for up to C$15m (A$16m). We arrive at an initial valuatio
22 Oct 2018
MGC Pharmaceuticals - Cannabis-based medicines and cosmetics
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
MGC Pharmaceuticals - Cannabis-based medicines and cosmetics
MGC Pharmaceuticals Ltd. (MXC:ASX) | 0 0 0.0% | Mkt Cap: 113.7m
- Published:
22 Oct 2018 -
Author:
Dr Dennis Hulme -
Pages:
18
MGC Pharmaceuticals is developing cannabis-based pharmaceutical products, initially in Australia and Europe. It has cannabis-growing operations in Europe and plans to supply cannabis-based active pharmaceutical ingredients (API), as well as developing registered pharmaceutical products for refractory epilepsy and dementia. MGC has signed a binding term sheet for the sale of its MGC Derma cannabis-based cosmetics business to Cannaglobal for up to C$15m (A$16m). We arrive at an initial valuatio